SCHEMBL6022685

SCHEMBL6022685

COc1ccc(-c2ccc(OCc3ccccc3)c(C34CC5CC(CC(C5)C3)C4)c2)cc1/C=C/C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC11 Q96DB2 4/20 0.55
RARB P10826 4/20 0.52
RARA P10276 3/20 0.52
RARG P13631 3/20 0.52
LMNA P02545 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NR1I2 O75469 1/20 0.52
PGR P06401 1/20 0.52
HSPD1 P10809 1/20 0.52
GOT1 P17174 1/20 0.52
GLRA1 P23415 1/20 0.52
BLM P54132 1/20 0.52
HSPE1 P61604 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HDAC2 Q92769 1/20 0.52
PTGER4 P35408 7/20 0.50
PTGER2 P43116 7/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022689 1.00 HDAC11 (0.55) HDAC11RARBRARARARGLMNA
SCHEMBL2387851 0.90 HDAC11 (0.48) HDAC11RARBRARARARGLMNA
SCHEMBL6022589 0.89 HDAC11 (0.55) HDAC11RARBRARARARGLMNA
SCHEMBL6022597 0.89 HDAC11 (0.55) HDAC11RARBRARARARGLMNA
SCHEMBL6022534 0.87 HDAC11 (0.56) HDAC11RARBRARARARGLMNA
SCHEMBL6022542 0.87 HDAC11 (0.56) HDAC11RARBRARARARGLMNA
SCHEMBL2394290 0.87 HDAC11 (0.48) HDAC11RARBRARARARGLMNA
SCHEMBL6023896 0.87 HDAC11 (0.55) HDAC11RARBRARARARGLMNA
SCHEMBL6023902 0.87 HDAC11 (0.55) HDAC11RARBRARARARGLMNA
SCHEMBL6023917 0.86 HDAC11 (0.57) HDAC11RARBLMNAHDAC2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 HDAC11 347/4885RARB 577/4885RARA 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.